SCHEMBL4448441

SCHEMBL4448441

Clc1nnc(Cl)c2c(Cl)cccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.48
CYP2A6 P11509 3/20 0.48
GOT1 P17174 1/20 0.41
NR4A2 P43354 2/20 0.38
MEN1 O00255 1/20 0.37
GFER P55789 1/20 0.37
KMT2A Q03164 1/20 0.37
CHEK1 O14757 1/20 0.36
FLT3 P36888 1/20 0.36
PLK3 Q9H4B4 1/20 0.36
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
PARP1 P09874 2/20 0.33
AHR P35869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146605 1.00 CYP1A2 (0.48) CYP1A2CYP2A6GOT1NR4A2MEN1
SCHEMBL8548327 0.78 ALDH1A1 (0.43) CYP1A2CYP2A6KMT2ALMNAALDH1A1
SCHEMBL31146637 0.77 GOT1 (0.38) CYP1A2CYP2A6GOT1MEN1GFER
SCHEMBL26118435 0.77 CYP2A6 (0.44) CYP1A2CYP2A6GOT1MEN1GFER
SCHEMBL3761582 0.77 GOT1 (0.38) CYP1A2CYP2A6GOT1MEN1GFER
SCHEMBL345211 0.73 GOT1 (0.62) CYP1A2CYP2A6GOT1MEN1GFER
SCHEMBL14375343 0.73 CYP1A2 (0.65) CYP1A2CYP2A6NR4A2MEN1KMT2A
SCHEMBL29365992 0.73 GOT1 (0.62) CYP1A2CYP2A6GOT1MEN1GFER
SCHEMBL31488270 0.73 DYRK1A (0.40) CYP1A2GOT1MEN1GFERKMT2A
SCHEMBL16057059 0.73 CYP2A6 (0.43) CYP2A6GOT1MEN1GFERKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) 2025-07-03 US disclosed
EP-4559521-A2 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2025-05-28 EP disclosed
EP-4404931-B1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) 2025-04-09 EP disclosed
EP-4458358-A1 PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY Tietze Chemical Consulting UG (DE) 2024-11-06 EP disclosed
EP-4404931-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2024-07-31 EP disclosed
WO-2023222865-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) 2023-11-23 WO disclosed
EP-4279074-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2023-11-22 EP disclosed
EP-2799435-B1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) 2018-03-28 EP disclosed
EP-2799435-B1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) 2018-03-28 EP disclosed
US-9718787-B2 Poly (ADP-ribose) polymerase inhibitor CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2017-08-01 US disclosed
US-9187430-B2 Poly (ADP-ribose) polymerase inhibitor CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-11-17 US disclosed
US-9187430-B2 Poly (ADP-ribose) polymerase inhibitor CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-11-17 US disclosed
US-20150051211-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-02-19 US disclosed
US-20150051211-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-02-19 US disclosed
US-20150051211-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) 2015-02-19 US disclosed
CN-103130723-B Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD 2015-01-14 CN disclosed
EP-2799435-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR Chengdu Di'ao Pharmaceutical Group Co. Ltd. (CN) 2014-11-05 EP disclosed
EP-2799435-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR Chengdu Di'ao Pharmaceutical Group Co. Ltd. (CN) 2014-11-05 EP disclosed
EP-2137162-A1 ORGANIC COMPOUNDS AND THEIR USES Novartis Ag (CH) 2009-12-30 EP disclosed
WO-2008110611-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051211-A1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR PARP1, PARP2, PARP11 CYP1A2 3644/4885CYP2A6 3595/4885GOT1 2405/4885
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES COL1A1, COL14A1, COL2A1 CYP1A2 405/4885CYP2A6 1319/4885GOT1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.